
|Articles|October 18, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemia
Author(s)Mark Weiss, MD
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.
Advertisement
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia, including BTK and PI3K inhibitors.
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?
Articles in this issue
over 12 years ago
Clinical Advances in Mantle Cell Lymphomaover 12 years ago
Emerging Therapies for the Treatment of Mantle Cell Lymphomaover 12 years ago
In Brief: Phase III Trials in Multiple Myelomaover 12 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?over 12 years ago
Transforming Expectations and Outcomes With Targeted Therapiesover 12 years ago
The Utility of Pomalidomide in R/R Multiple MyelomaAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5

















